Crown Biosciences Inc., of San Diego, published preclinical data in the Journal of the National Cancer Institute in conjunction with Carsgen Therapeutics Ltd., of Shanghai, and the Shanghai Cancer Institute showing CLDN18.2 targeting CAR T cells can eliminate gastric tumors in a PDX mouse model.